Literature DB >> 19414071

Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1.

Lauren Monovich1, Keith A Koch, Robin Burgis, Ekundayo Osimboni, Thierry Mann, Daniel Wall, Jinhai Gao, Yan Feng, Richard B Vega, Benjamin A Turner, David B Hood, Andy Law, Philip J Papst, David Koditek, Joseph A Chapo, Brian G Reid, Lawrence S Melvin, Nikos C Pagratis, Timothy A McKinsey.   

Abstract

Histone deacetylase 5 (HDAC5) represses expression of nuclear genes that promote cardiac hypertrophy. Agonism of a variety of G protein coupled receptors (GPCRs) triggers phosphorylation-dependent nuclear export of HDAC5 via the CRM1 nuclear export receptor, resulting in derepression of pro-hypertrophic genes. A cell-based high-throughput screen of a commercial compound collection was employed to identify compounds with the ability to preserve the nuclear fraction of GFP-HDAC5 in primary cardiomyocytes exposed to GPCR agonists. A hit compound potently inhibited agonist-induced GFP-HDAC5 nuclear export in cultured neonatal rat ventricular myocytes (NRVMs). A small set of related compounds was designed and synthesized to evaluate structure-activity relationship (SAR). The results demonstrated that inhibition of HDAC5 nuclear export was a result of compounds irreversibly reacting with a key cysteine residue in CRM1 that is required for its function. CRM1 inhibition by the compounds also resulted in potent suppression of cardiomyocyte hypertrophy. These studies define a novel class of anti-hypertrophic compounds that function through irreversible inhibition of CRM1-dependent nuclear export.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414071     DOI: 10.1016/j.bbagrm.2009.04.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Atomic basis of CRM1-cargo recognition, release and inhibition.

Authors:  Ho Yee Joyce Fung; Yuh Min Chook
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

Review 2.  Three 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC.

Authors:  Mazen Kurdi; George W Booz
Journal:  J Mol Cell Cardiol       Date:  2011-02-19       Impact factor: 5.000

Review 3.  A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.

Authors:  Lillianne H Wright; Donald R Menick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-20       Impact factor: 4.733

Review 4.  Intrinsic and extrinsic negative regulators of nuclear protein transport processes.

Authors:  Toshihiro Sekimoto; Yoshihiro Yoneda
Journal:  Genes Cells       Date:  2012-06-07       Impact factor: 1.891

Review 5.  Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.

Authors:  Kate L Weeks; Metin Avkiran
Journal:  J Physiol       Date:  2014-11-25       Impact factor: 5.182

Review 6.  Histone deacetylase signaling in cardioprotection.

Authors:  Lorenz H Lehmann; Barbara C Worst; David A Stanmore; Johannes Backs
Journal:  Cell Mol Life Sci       Date:  2013-12-06       Impact factor: 9.261

7.  Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts.

Authors:  Mirna N Chahine; Maxime Mioulane; Markus B Sikkel; Peter O'Gara; Cristobal G Dos Remedios; Grant N Pierce; Alexander R Lyon; Gábor Földes; Sian E Harding
Journal:  Cardiovasc Res       Date:  2014-10-23       Impact factor: 10.787

8.  β-Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC5) Nuclear Accumulation in Cardiomyocytes by B55α-PP2A-Mediated Dephosphorylation.

Authors:  Kate L Weeks; Antonella Ranieri; Agnieszka Karaś; Bianca C Bernardo; Alexandra S Ashcroft; Chris Molenaar; Julie R McMullen; Metin Avkiran
Journal:  J Am Heart Assoc       Date:  2017-03-25       Impact factor: 5.501

Review 9.  Inhibiting cancer cell hallmark features through nuclear export inhibition.

Authors:  Qingxiang Sun; Xueqin Chen; Qiao Zhou; Ezra Burstein; Shengyong Yang; Da Jia
Journal:  Signal Transduct Target Ther       Date:  2016-07-01

10.  Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.

Authors:  J Etchin; Q Sun; A Kentsis; A Farmer; Z C Zhang; T Sanda; M R Mansour; C Barcelo; D McCauley; M Kauffman; S Shacham; A L Christie; A L Kung; S J Rodig; Y M Chook; A T Look
Journal:  Leukemia       Date:  2012-07-31       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.